Dettagli della rivista
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Accesso libero

Shedding light on weight loss: A narrative review of medications for treating obesity

Pubblicato online: 26 Sep 2023
Volume & Edizione: AHEAD OF PRINT
Pagine: -
Ricevuto: 22 Jul 2023
Dettagli della rivista
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno

GUPTA V, MUNJAL JS, JHAJJ P, JHAJJ S, JAIN R. Obesity and Atrial Fibrillation: A Narrative Review. Cureus. 2022;14(11):e31205. Search in Google Scholar

DE LORENZO A, GRATTERI S, GUALTIERI P, CAMMARANO A, BERTUCCI P, DI RENZO L. Why primary obesity is a disease?. J Transl Med. 2019;17(1):169. Search in Google Scholar

LIN X, LI H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol (Lausanne). 2021;12:706978. Search in Google Scholar

ANAM, M., MAHARJAN, S., AMJAD, Z., ABAZA, A., VASAVADA, AM., SADHU, A., et al. Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). Cureus, 14(12), e32610. Search in Google Scholar

WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: World Health Organization; 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-over Search in Google Scholar

CENTERS FOR DISEASE CONTROL AND PREVENTION. National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. 27 September 2022. Available at: https://www.cdc.gov/ Search in Google Scholar

SINGH G, KRAUTHAMER M, BJALME-EVANS M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. Search in Google Scholar

MOHAMMED MS, SENDRA S, LLORET J, BOSCH I. Systems and WBANs for Controlling Obesity. J Healthc Eng. 2018;2018:1564748. Search in Google Scholar

PANUGANTI KK, NGUYEN M, KSHIRSAGAR RK. Obesity. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Search in Google Scholar

HASLAM DW, JAMES WP. Obesity. Lancet. 2005;366(9492):1197-1209. Search in Google Scholar

THE LANCET DIABETES ENDOCRINOLOGY. Lets talk about obesity. Lancet Diabetes Endocrinol. 2023;11(4):217. Search in Google Scholar

WIECHERT M, HOLZAPFEL C. Nutrition Concepts for the Treatment of Obesity in Adults. Nutrients. 2021 Dec 30;14(1):169. Search in Google Scholar

YUMUK, V., TSIGOS, C., FRIED, M., SCHINDLER, K., BUSETTO, L., MICIC, D., et al. European Guidelines for Obesity Management in Adults. Obesity facts, 8(6), 402–424. Search in Google Scholar

COHEN JB, GADDE KM. Weight Loss Medications in the Treatment of Obesity and Hypertension. Curr Hypertens Rep. 2019;21(2):16. Search in Google Scholar

SON JW, KIM S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes Metab J. 2020;44(6):802-818. Search in Google Scholar

AJOOLABADY, A., LIU, S., KLIONSKY, DJ., LIP, GYH., TUOMILEHTO, J., KAVALAKATT, S., et al. ER stress in obesity pathogenesis and management. Trends in pharmacological sciences, 43(2), 97–109. Search in Google Scholar

LEE KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 2001;54 Suppl 2:S29-S33. Search in Google Scholar

ARCARO, G., ZAMBONI, M., ROSSI, L., TURCATO, E., COVI, G., ARMELLINI, F., BOSELLO, O.et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 23(9), 936–942. Search in Google Scholar

POIRIER, P., GILES, TD., BRAY, GA., HONG, Y., STERN, JS., PI-SUNYER, FX. et al. American Heart Association, & Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation, 113(6), 898–918. Search in Google Scholar

YUDKIN JS, STEHOUWER CD, EMEIS JJ, COPPACK SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol. 1999;19(4):972-978. Search in Google Scholar

CIGOLINI M, TARGHER G, BERGAMO ANDREIS IA, TONOLI M, AGOSTINO G, DE SANDRE G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16(3):368-374. Search in Google Scholar

MOHAMED-ALI, V., GOODRICK, S., RAWESH, A., KATZ, D. R., MILES, J. M., YUDKIN, J. S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. The Journal of clinical endocrinology and metabolism.1997; 82(12), 4196–4200. Search in Google Scholar

RIDKER PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000;45:391-418. Search in Google Scholar

ROCHA VZ, LIBBY P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399–409. Search in Google Scholar

ROSS R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(pt 2):S419–S420. Search in Google Scholar

IACOBELLIS G. Epicardial and pericardial fat: close, but very different. Obesity (Silver Spring). 2009;17(4):625; author reply 626-7. Search in Google Scholar

POWELL-WILEY, TM., POIRIER, P., BURKE, LE., DESPRÉS, JP., GORDON-LARSEN, P., LAVIE, CJ., et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21), e984–e1010. Search in Google Scholar

ROSITO, GA., MASSARO, JM., HOFFMANN, U., RUBERG, FL., MAHABADI, AA., VASAN, RS., O’DONNELL, CJ., et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation.2008; 117(5), 605–613. Search in Google Scholar

FOX, CS., MASSARO, JM., HOFFMANN, U., POU, KM., MAUROVICH-HORVAT, P., LIU, CY., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation.2007; 116(1), 39–48. Search in Google Scholar

VEGA GL, ADAMS-HUET B, PESHOCK R, WILLETT D, SHAH B, GRUNDY SM. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab. 2006;91(11):4459-4466. Search in Google Scholar

POU, KM., MASSARO, JM., HOFFMANN, U., VASAN, RS., MAUROVICH-HORVAT, P., LARSON, MG., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation2007; 116(11), 1234–1241. Search in Google Scholar

TAGUCHI, R., TAKASU, J., ITANI, Y., YAMAMOTO, R., YOKOYAMA, K., WATANABE, S., et al. Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis. 2001;157(1): 203–209. Search in Google Scholar

JEONG, JW., JEONG, MH., YUN, KH., OH, SK., PARK, EM., KIM, YK., et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circulation journal : official journal of the Japanese Circulation Society.2007; 71(4):536–539. Search in Google Scholar

MONTAN PD, SOURLAS A, OLIVERO J, SILVERIO D, GUZMAN E, KOSMAS CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019;7(16):393. Search in Google Scholar

GADDE KM. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. Expert Opin Pharmacother. 2014;15(6):809-822. Search in Google Scholar

COULTER AA, REBELLO CJ, GREENWAY FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018;78(11):1113-1132. Search in Google Scholar

PATEL DK, STANFORD FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130(2):173-182. Search in Google Scholar

YANOVSKI SZ, YANOVSKI JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86. Search in Google Scholar

RODGERS RJ, TSCHÖP MH, WILDING JP. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621-626. Search in Google Scholar

MORDES JP, LIU C, XU S. Medications for weight loss. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):91-7. Search in Google Scholar

VOSBURG, RW., EL CHAAR, M., EL DJOUZI, S., DOCIMO, S., JR, CHOI, D., LAMASTERS, T., et al. Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.2022; 18(9):1109–1119. Search in Google Scholar

FUJIOKA K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring). 2015;23 Suppl 1:S7-11. Search in Google Scholar

WOODARD K, LOUQUE L, HSIA DS. Medications for the treatment of obesity in adolescents. Ther Adv Endocrinol Metab. 2020;11:2042018820918789. Search in Google Scholar

VELAZQUEZ A, APOVIAN CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018; 1411(1):106-119. Search in Google Scholar

LEI XG, RUAN JQ, LAI C, SUN Z, YANG X. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2021;29(6):985-994. Search in Google Scholar

TORGERSON JS, HAUPTMAN J, BOLDRIN MN, SJÖSTRÖM L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004 Mar;27(3):856]. Diabetes Care. 2004;27(1):155-161. Search in Google Scholar

APOVIAN CM. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future Cardiol. 2016;12(2):129-138. Search in Google Scholar

KÜHNEN, P., CLÉMENT, K., WIEGAND, S., BLANKENSTEIN, O., GOTTESDIENER, K., MARTINI, LL., et al. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. The New England journal of medicine.2016;375(3), 240–246. Search in Google Scholar

TCHANG BG, TARAZI MS, ARAS M, SHUKLA AP. An update on pharmacotherapeutic strategies for obesity. Expert Opin Pharmacother. 2021;22(10):1305-1318. Search in Google Scholar

HEYMSFIELD, SB., COLEMAN, LA., MILLER, R., ROOKS, DS., LAURENT, D., PETRICOUL, O., et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA network open, 4(1), e2033457. Search in Google Scholar

HUGHES TE, KIM DD, MARJASON J, PROIETTO J, WHITEHEAD JP, VATH JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782-8. Search in Google Scholar

GRUNVALD E, SHAH R, HERNAEZ R, CHANDAR AK, PICKETT-BLAKELY O, TEIGEN LM, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198-1225. Search in Google Scholar

GIUGLIANO, D., MAIORINO, MI., BELLASTELLA, G., LONGO, M., CHIODINI, P., ESPOSITO, K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes, obesity & metabolism.2019; 21(11):2576–2580. Search in Google Scholar

BONORA, E., FRIAS, JP., TINAHONES, FJ., VAN, J., MALIK, RE., YU, Z., et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes, obesity & metabolism.2021;23(10), 2242–2250. Search in Google Scholar

DOGGRELL S. A. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?. Expert opinion on investigational drugs.2023;32(5), 355–359. Search in Google Scholar

Articoli consigliati da Trend MD